Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis
Study Details
Study Description
Brief Summary
The investigators aim to retrospectively explore the electronic medical records of all patients who were admitted to the Intensive Care Unit (ICU) of the UZ Brussels in the last 10 years (March 1st 2011- March 1st 2021) and who received prolonged sedation (>24h) with sevoflurane.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Sevoflurane group Patients that received sevoflurane while in ICU care. |
Drug: Sevoflurane
Sevoflurane administration to sedate the patient
|
Outcome Measures
Primary Outcome Measures
- Nephrogenic Diabetes Insipidus prevalence [up to 8 weeks]
How many patients under sevoflurane sedation ultimately develop NDI? NDI confirmed by demonstrating the absence of a urine concentrating response to exogenous Arginine Vasopressine.
Secondary Outcome Measures
- Number of patients that develop risk factors of NDI [up to 8 weeks]
Number of patients that develop risk factors (electrolyte disorder, urinary obstruction) for NDI.
- Amount of time patient was placed under sevoflurane sedation. [up to 8 weeks]
How long are they under sevoflurane sedation.
- Number of patients with electrolyte abnormalities as assessed by lab results. [during hospitalization, up to 8 weeks.]
Lab results of hematology and chemistry labs show an electrolyte imbalance.
- Number of patients with excessive urine output [during hospitalization, up to 8 weeks.]
Amount of urine output: >40 ml/kg/24h
- Number of patients with an abnormal physical examination. [during hospitalization, up to 8 weeks.]
Typical physical symptoms of (N)DI: tired, lethargic, tachycardia, tachypnea, hypotension and dry mucous membranes.
- Number of patients with urine with an abnormal osmolality [during hospitalization, up to 8 weeks.]
Lab testing of urine: osmolality < 300 mosm/kg
- Number of patients that show an abnormal amount of fluid intake [during hospitalization, up to 8 weeks.]
>2.5l/day
- Number of patients that have an abnormal abdominal echo of the bladder. [during hospitalization, up to 8 weeks.]
Echo shows an enlarged bladder.
- Number of symptoms of NDI [up to 8 weeks]
Number of symptoms of NDI do these patients show?
- Timing of symptoms of NDI [up to 8 weeks]
After how much time do these patients show symptoms of NDI?
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Sevoflurane administration >24h
-
18 years and older
Exclusion Criteria:
-
< 18 years old
-
Pre-existing diabetes insipidus
-
Use of drugs at risk for diabetes insipidus (including lithium, cisplatin)
-
Hypercalcemia (persistently >2.75 mmol/L)
-
Pituitary or acute brain surgery
-
Patients requiring continuous renal replacement therapy
-
Pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UZ Brussel | Jette | Brussel | Belgium | 1090 |
Sponsors and Collaborators
- Universitair Ziekenhuis Brussel
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Sevoflu-DI-IZ